Dr Kate Burbury is consultant haematologist; stream lead for myeloproliferative disorders (MPD)/chronic myeloid leukaemia (CML) and lead clinician for haemostasis, thrombosis and peri-operative optimisation, including pre-habilitation, for all major cancer surgery patients at the VCCC.  Kate is a member of professional societies, scientific committees, council member for Haematology Society for Australia and New Zealand, and actively involved in the development of expert guidelines and governance structures for both the institution and external working parties, including European Leukaemia Network: flow cytometry in myelodysplastic syndromes (MDS).  Kate has an active research programme, with a particular interest in MPD, CML, FC in MDS and the haemostatic/endothelial dysfunction associated with malignancy. She has an extensive portfolio in clinical trials, published numerous peer-reviewed manuscripts, regular presents at national and international scientific meetings, a member of editorial boards and reviewer for numerous journals. Kate is committed to clinical and translational research, and the provision of the best care to patients through their treatment journey.

Her main interest in MPD, CML, FC in MDS and the haemostatic/endothelial dysfunction associated with malignancy